Mirabilis系统原型机用于超声引导体积壳消融技术快速无创治疗子宫肌瘤的初步研究
这项多中心前瞻性单臂初步研究评估了经腹高强度聚焦超声(HIFU)原型设备以「壳消融」技术治疗症状性子宫肌瘤的安全性和急性组织消融效果,73例患者分开发队列(37例)和验证队列(36例)。所有患者均未报告严重不良器械事件,验证队列平均非灌注体积44.9±58.5 cm³、平均治疗时间3.6±2.1分钟,部分患者亚组的生活质量评分和肌瘤体积在3-6个月时有显著改善。
要点
- 73例症状性子宫肌瘤患者接受经腹超声引导HIFU壳消融,无严重不良器械事件报告。
- 验证队列平均非灌注体积44.9±58.5 cm³,平均总治疗时间3.6±2.1分钟。
- 部分患者亚组生活质量评分中位提高16.5分(p=.011),肌瘤体积平均缩小24.0%(p=.013)。
核心结论
- 超声引导HIFU原型设备消融展示了极好的安全性,使用最终验证的治疗参数在平均总治疗时间不足4分钟内产生了临床相关的非灌注体积。
- 在部分患者亚组中评估的短期临床疗效指标令人鼓舞,应开展更大规模研究以确认这些结果(ClinicalTrials.gov,NCT01946178)。
研究设计与样本
- 多中心前瞻性单臂初步研究(加拿大特别工作组分类II-2)。
- 设置:大学附属教学医院和私立社区医院。
- 患者:诊断为症状性子宫肌瘤、计划行子宫切除术的女性。
- 干预:73名女性接受经腹超声引导HIFU治疗,采用称为「壳消融」的体积消融技术,将HIFU能量以部分包裹目标肌瘤周边区域的模式沉积。
- 患者分为2个连续队列:开发队列(最先治疗的37例患者)和验证队列(最后治疗的36例患者);开发队列治疗用于剂量探索以确定最佳HIFU治疗参数,验证队列治疗用于验证这些最终设置。
主要发现
- 65例患者(89.0%)在治疗前仅接受预防性口服、舌下或肌肉注射镇痛,有时联合口服抗焦虑药;其余8例患者(11.0%)在治疗前接受麻醉。
- 67例患者(91.8%)在治疗完成后0至179天之间按计划行子宫切除术;不良事件监测至研究退出,时间为治疗后10至191天。
- 全部73例患者的主要疗效终点为非灌注体积(NPV),于治疗后0至7天通过子宫切除术后组织切片或钆增强磁共振成像评估。
- 开发队列平均NPV为17.9±24.9 cm³(范围0-123.0),平均总治疗时间4.9±2.4分钟(范围1.1-11.3);验证队列平均NPV为44.9±58.5 cm³(范围0-284.7),平均总治疗时间3.6±2.1分钟(范围1.5-9.5)。
- 在数据可用的患者亚组中,生活质量评分中位提高16.5分(p=.011),症状严重程度评分中位降低13.5分(p=.254),治疗肌瘤体积平均缩小24.0%(p=.013);8例基线月经失血量评分高于平均水平且随访期间月经周期长度规则的患者,月经失血量评分中位降低40.8%(p=.035)。
临床怎么用
- 原文未据此给出推荐;作者结论指出短期临床疗效指标令人鼓舞,应开展更大规模研究以确认这些结果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: The primary objective of this pilot study was to evaluate the safety and acute tissue ablation efficacy of a transabdominal high-intensity focused ultrasound (HIFU) prototype device that uses ultrasound imaging guidance for rapid noninvasive ablation of uterine myomas. The secondary objective was to assess preliminary myoma-related symptom improvement and myoma volume reduction at 3 to 6 months post-treatment in subsets of patients. DESIGN: Multicenter prospective single-arm pilot study (Canadian Task Force classification II-2). SETTING: University-affiliated teaching hospital and private community hospital. PATIENTS: Women with a diagnosis of symptomatic uterine myomas planning to undergo hysterectomy. INTERVENTIONS: Seventy-three women underwent transabdominal ultrasound-guided HIFU treatment using a volumetric ablation technique referred to as "shell ablation," in which the HIFU energy is deposited in patterns that partially encapsulate the peripheral region of the targeted myoma(s). Patients were divided into 2 sequential cohorts, the development cohort (the first 37 patients treated) and the validation cohort (the final 36 patients treated). Development cohort treatments were performed for dose-ranging purposes to identify the optimum HIFU treatment parameters, whereas the validation cohort treatments were performed to validate these final settings. Sixty-five patients (89.0%) received only prophylactic oral, sublingual, or intramuscular analgesia before treatment, sometimes with oral anxiolytics. The remaining 8 patients (11.0%) were anesthetized before treatment. Sixty-seven patients (91.8%) then had scheduled hysterectomies between 0 and 179 days after treatment completion. Adverse events were monitored until study exit, which ranged from 10 to 191 days post-treatment. MEASUREMENTS AND MAIN RESULTS: The primary efficacy endpoint measured in all 73 patients was the nonperfused volume (NPV) of tissue produced, which was assessed between 0 and 7 days post-treatment either by tissue sectioning after hysterectomy or by gadolinium-enhanced magnetic resonance imaging. Secondary efficacy endpoints were also measured in subsets of patients who were prospectively scheduled for delayed hysterectomies: Changes in menstrual blood loss (MBL), symptom severity (SS), and quality of life (QOL) scores were assessed using validated techniques at 3 months post-treatment in 10 patients and changes in treated myoma volume were assessed using magnetic resonance imaging at 3 to 6 months post-treatment in 14 patients. In all 73 patients, there were no reports of any serious adverse device effects, including no damage to any extrauterine collateral tissues or the abdominal skin. In the development cohort, a mean NPV of 17.9 ± 24.9 cm3 (range, 0-123.0) was produced in a mean total treatment time of 4.9 ± 2.4 minutes (range, 1.1-11.3). These metrics improved in the validation cohort, where a mean NPV of 44.9 ± 58.5 cm3 (range, 0-284.7) was produced in a mean total treatment time of 3.6 ± 2.1 minutes (range, 1.5-9.5). In the subsets of patients with data available, there was a significant improvement in QOL score (median, 16.5 point increase; p = .011), an improving trend in SS score (median, 13.5 point decrease; p = .254), and a significant improvement in treated myoma volume (mean, 24.0% decrease; p = .013). In 8 patients who had above-average MBL scores at baseline and regular menstrual cycle lengths during follow-up, there was also a significant improvement in MBL score (median, 40.8% decrease; p = .035). CONCLUSION: Ultrasound-guided HIFU ablation with the prototype device demonstrated an excellent safety profile and produced clinically relevant NPVs in a mean total treatment time of under 4 minutes using the final validated treatment settings. Short-term clinical efficacy metrics assessed in subsets of patients were encouraging, and larger studies should be conducted to confirm these results (ClinicalTrials.gov, NCT01946178).
引用
- Parsons JE, Lau MPH, Martin PJ, et al. Pilot Study of the Mirabilis System Prototype for Rapid Noninvasive Uterine Myoma Treatment Using an Ultrasound-Guided Volumetric Shell Ablation Technique. J Minim Invasive Gynecol. 2017. PMID: 28109895. doi:10.1016/j.jmig.2017.01.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。